SEARCH

SEARCH BY CITATION

References

  • 1
    Han T., Ozer H., Gavigan M., et al. Benign monoclonal B cell lymphocytosis — A benign variant of CLL: clinical, immunologic, phenotypic and cytogenetic studies in 20 patients. Blood 1984; 64:24452.
  • 2
    Han T., Sokal JE. Spontaneous remission of leukemic lymphoproliferative disease. Cancer 1971; 27:58695.
  • 3
    Ribera JM, Vinolas N., Urbano-Ispizua A., Gallart T., Montserrat E., Rozman C. “Spontaneous” complete remissions in chronic lymphocytic leukemia: Report of three cases and review of the literature. In: Blood cells. New York: Springer Verlag, 1987; 12:4719.
  • 4
    Garcia C., Rosén A., Kimby E., et al. Higher T cell imbalance and growth factor receptor expression in B cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B cell lymphocytosis of undetermined significance (B-MLUS). Leukemia Res 1989; 13:317.
  • 5
    Kimby E., Mellstedt H., Nilsson B., Tribukait B., Björkholm M., Holm G. S-phase lymphocytes in chronic lymphocytic leukemia (CLL) in relation to immunoglobulin isotype on the leukemic clone and to disease activity. Leukemia 1987; 1:4326.
  • 6
    Reichert RA, Gallatin M., Weissman IL, Butcher EC. Germinal center B cells lack homing receptors necessary for normal lymphocyte recirculation. J Exp Med 1983; 157:81327.
  • 7
    Hsu S-M, Jaffe ES. Phenotypic expression of B-lymphocytes. I. Identification with monoclonal antibodies in normal lymphoid tissues. Am J Pathol 1984; 114:38795.
  • 8
    Dörken B., Moldenhauer G., Pezzutto A., et al. HD39 (B3), a B lineage-restricted antigen whose cell surface expressin is limited to resting and activated human B lymphocytes. J Immunol 1986; 136:44709.
  • 9
    Ideström K., Kimby E., Björkholm M., et al. Treatment of chronic lymphocytic leukemia and well differentiated lymphocytic lymphoma with continous low or intermittent high dose prednimustine versus chlorambucil/prednisolone. Eur J Cancer Clin Oncol 1982; 11:111723.
  • 10
    Silver RT, Sawitsky A., Rai KR, Holland JF, Glidewell O. Guidelines for protocol studies in chronic lymphocytic leukemia. Am J Hematol 1978; 4:34358.
  • 11
    Holm G., Pettersson D., Mellstedt H., Hedfors E., Bloth B. Lymphocyte subpopulations in peripheral blood of healthy persons. Characterization by surface markers and lack of selection during purification. Clin Exp Immunol 1975; 20:44357.
  • 12
    Pettersson D., Mellstedt H., Holm G. IgG on human blood lymphocytes studied by immunofluoroscence. Scand J Immunol 1978; 8:52542.
  • 13
    Mellstedt H., Holm G., Pettersson D., et al. T cells in monoclonal gammopathies. Scand J Haematol 1982; 29:5764.
  • 14
    Lutz W. Statistical methods as applied to immunological data. In: WeirDM, ed. Handbook of Experimental Immunology. Oxford: Blackwell Scientific Publications, 1967, p. 1163.
  • 15
    Moldenhauer G., Dörken B., Schwartz R., Pezzutto A., Hammerling GJ. Characterization of human B lymphocyte-specific antigen defined by monoclonal antibodies HD6 and HD39. In: ReinherzEL, HaynesBF, NadlerLM, BersteinID, eds. Leukocyte Typing II. Berlin: Springer-Verlag, 1986; 2:97107.
  • 16
    Mason DY, Stein H., Gerdes J., et al. Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 1987; 69:83640.
  • 17
    Nadler LM. B-cell leukemia panel workshop: summary and comments. In: ReinherzEL, HaynesBF, NadlerLM, BernsteinID, eds. Leukocyte Typing II. New York: Springer-Verlag 1986; 2:1343.
  • 18
    Resegotti L., Palestro G., Novero D., et al. Immunological cell markers of peripheral blood and lymph node lymphocytes in chronic lymphocytic leukemia. Leukemia Res 1987; 11:42936.
  • 19
    Melchers F., Lernhardt W. Three restriction points in the cell cycle of activated murine B lymphocytes. Proc Natl Acad Sci USA 1985; 82:76815.
  • 20
    Carlsson M., Tötterman TH, Mattsson P., Nilsson K. Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA. Blood 1988; 71:41521.
  • 21
    Kay NE, Burton J., Wagner D., Nelson DL. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood 1988; 72:44750.
  • 22
    Lantz O., Grillot-Courvalin C., Schmitt C., Fermand J-P, Brouet J-C. Interleukin 2-induced proliferation or leukemic human B cells. J Exp Med 1985; 161:122530.
  • 23
    Giovarelli M., Foa R., Benetton G., Lusso P., Fierro M., Forni G. Release of interleukin-2-like material by B-chronic lymphocytic leukemia cells. An autocrine or paracrine model of production and utilization. Leukemia Res 1988; 12:2019.
  • 24
    Sutherland R., Delia D., Schneider C., Neuman R., Kemshead J., Greaves M. Ubiquitous cell-surface glycoprotein on tumor cell is proliferation-associated receptor for transferrin. Proc Natl Acad Sci USA 1981; 78:45158.
  • 25
    Larrick JW, Logue G. Transferrin receptors on leukemic cells. Lancet 1980; ii:8623.
  • 26
    Larrick JW, Creswell P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 1979; 11:57986.
  • 27
    Schwartz R., Moldenhauer G., Dörken B., Pezzutto A., Momburg F., Schirrmacher V. TPA-induced modulation of B cell differentiation antigens defined by monoclonal antibodies (HD6, HD28, HD37, HD39). In: ReinherzEL, HaynesBF, NadlerLM, BernsteinID, eds. Leukocyte Typing II. New York: Springer-Verlag, 1986; 2:52740.
  • 28
    Kansas GS, Wood GS, Fishwild DM, Engleman EG. Functional characterization of human T lymphocyte subsets distinguished by monoclonal anti-Leu-8. J Immunol 1985; 134:29953002.
  • 29
    Kansas GS, Wood GS, Engleman EG. Maturational and functional diversity of human B lymphocytes delineated with anti-Leu-8. J Immunol 1985; 134:30036.